News

G2G Wants Your Input to Contribute to New ARPA-H Initiative

The White House Office of Science & Technology Policy (OSTP) is establishing the framework for the Advanced Research Projects Agency-Health (ARPA-H) that was included in President Biden’s FY2022 budget. Modeled after the Defense Advanced Research Projects Agency (DARPA), ARPA-H would tackle bold challenges requiring large-scale, cross-sector coordination, employing a non-traditional and nimble approach to high-risk research. Specifically, under Director Eric Lander, PhD from the Broad Institute and MIT who was sworn in as the first Cabinet level Director of OSTP on June 2, 2021, ARPA-H will advance translational science and drive transformational health innovations that tackle gaps in the system and implement health breakthroughs.

G2G is participating in efforts to contribute input to help shape how ARPA-H will function and we would love to hear your thoughts and questions you would like us to address as we continue our dialogue with the OSTP and ARPA-H leadership.

Click here to provide G2G with your feedback.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and